Retatrutide

Overview

Retatrutide (LY3437943) is a novel single-molecule triple agonist that activates three incretin-related receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. Developed by Eli Lilly, it represents a new class of multi-receptor metabolic research compounds. Phase 2 clinical data published in the New England Journal of Medicine demonstrated significant effects on body weight and metabolic parameters, making it one of the most studied compounds in contemporary metabolic research.

Mechanism of Action

Retatrutide simultaneously engages three G-protein-coupled receptors. GLP-1 receptor activation slows gastric emptying and promotes satiety signalling via hypothalamic pathways. GIP receptor agonism enhances insulin secretion and may contribute to adipose tissue regulation. Glucagon receptor activation — the distinguishing feature from dual agonists — increases hepatic energy expenditure and lipid oxidation. The combined triple-receptor engagement produces synergistic effects on energy balance not achievable through any single receptor pathway.

Research Applications

• Multi-receptor metabolic pathway research
• Body composition and energy balance studies
• Incretin system pharmacology investigation
• Hepatic lipid metabolism and glucagon signalling
• Comparative efficacy studies vs mono/dual agonists